Zobrazeno 1 - 10
of 1 689
pro vyhledávání: '"F. Smit"'
Autor:
F. Benz, L. Grolig, S. Hannibal, C. Buntrock, P. Cuijpers, K. Domschke, D. D. Ebert, J. Ell, M. Janneck, C. Jenkner, A. F. Johann, A. Josef, M. Kaufmann, A. Koß, T. Mallwitz, H. Mergan, C. M. Morin, D. Riemann, H. Riper, S. R. Schmid, F. Smit, L. Spille, L. Steinmetz, E. J. W. Van Someren, K. Spiegelhalder, D. Lehr
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Background Insomnia is a highly prevalent disorder associated with numerous adverse health outcomes. Cognitive behavioural therapy for insomnia (CBT-I) is recommended as first-line treatment by clinical guidelines but is accessible to only a
Externí odkaz:
https://doaj.org/article/13736233927b4f3d98ad1be2091300e9
Autor:
Anastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, Kelly Hoefakker, Bimal Prajapati, Amrita Singh, Annemarie Boerma, Marieke van der Heiden, Sjoukje F. Oosting, Astrid A. M. van der Veldt, T. Jeroen N. Hiltermann, Corine H. GeurtsvanKessel, Anne-Marie C. Dingemans, Egbert F. Smit, Elisabeth G. E. de Vries, John B. A. G. Haanen, Pia Kvistborg, Debbie van Baarle
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionResearch has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood.M
Externí odkaz:
https://doaj.org/article/80fab91389fd443aa2a12002abce5698
Autor:
Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, Benoît P. Nicolet, Marleen M. van Loenen, Kim Monkhorst, Alexander A.F.A. Veenhof, Egbert F. Smit, Koen J. Hartemink, John B.A.G. Haanen, Rosa de Groot, Monika C. Wolkers
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has proven highly effective for treating solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy for yet unknown reasons. Defin
Externí odkaz:
https://doaj.org/article/765f3c5d599a4883af3b95a3fce40f0d
Autor:
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D Schouten, Michel M van den Heuvel, Daniela S Thommen, Egbert F Smit, Gerrit A Meijer, Kim Monkhorst
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0293707 (2024)
BackgroundThe efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadeq
Externí odkaz:
https://doaj.org/article/6b18e0bcb87f45658fff43824048aa27
Autor:
Sophie M. Ernst, Joanne M. Mankor, Job van Riet, Jan H. von der Thüsen, Hendrikus J. Dubbink, Joachim G.J.V. Aerts, Adrianus J. de Langen, Egbert F. Smit, Anne-Marie C. Dingemans, Kim Monkhorst
Publikováno v:
Journal of Thoracic Oncology, 18(4), 487-498. International Association for the Study of Lung Cancer
Introduction: Patient-reported smoking history is frequently used as a stratification factor in NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the mutational processes in a tumor. Next-generation sequencing
Autor:
Tomohide Tamura, Kazumasa Noda, Shinzoh Kudoh, José Baselga, Johan Vansteenkiste, Giuseppe Giaccone, Seiji Yano, Takeshi Horai, Kazuhiko Nakagawa, Ichiro Takata, Rui Ping Dong, Masahiro Fukuoka, Egbert F. Smit, Jean-Yves Douillard, Danny Rischin, Richard Eek, A. Feyereislova, Steven D. Averbuch, Yutaka Nishiwaki, Angela Macleod
Publikováno v:
Journal of Clinical Oncology. 41:1162-1171
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung
Autor:
Ard van Veelen, Judith Gulikers, Lizza E.L. Hendriks, Safiye Dursun, Juanita Ippel, Egbert F. Smit, Anne-Marie C. Dingemans, Robin van Geel, Sander Croes
Publikováno v:
van Veelen, A, Gulikers, J, Hendriks, L E L, Dursun, S, Ippel, J, Smit, E F, Dingemans, A-M C, van Geel, R & Croes, S 2022, ' Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer : The OSIBOOST trial ', Lung Cancer, vol. 171, pp. 97-102 . https://doi.org/10.1016/j.lungcan.2022.07.012
Lung Cancer, 171, 97-102. Elsevier Ireland Ltd
Lung Cancer, 171, 97-102. Elsevier Ireland Ltd
Introduction: Exposure to osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treatment of non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation, can be substantially below average.
Autor:
G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen
Publikováno v:
EClinicalMedicine, 59:101955. Lancet Publishing Group
EClinicalMedicine, 59:101955. Elsevier
Veerman, G D M, Boosman, R J, Jebbink, M, Oomen-de Hoop, E, van der Wekken, A J, Bahce, I, Hendriks, L E L, Croes, S, Steendam, C M J, de Jonge, E, Koolen, S L W, Steeghs, N, van Schaik, R H N, Smit, E F, Dingemans, A-M C, Huitema, A D R & Mathijssen, R H J 2023, ' Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer ', EClinicalMedicine, vol. 59, 101955 . https://doi.org/10.1016/j.eclinm.2023.101955
EClinicalMedicine, 59:101955. Elsevier
Veerman, G D M, Boosman, R J, Jebbink, M, Oomen-de Hoop, E, van der Wekken, A J, Bahce, I, Hendriks, L E L, Croes, S, Steendam, C M J, de Jonge, E, Koolen, S L W, Steeghs, N, van Schaik, R H N, Smit, E F, Dingemans, A-M C, Huitema, A D R & Mathijssen, R H J 2023, ' Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer ', EClinicalMedicine, vol. 59, 101955 . https://doi.org/10.1016/j.eclinm.2023.101955
Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (EGFRm+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimertinib is a
Autor:
William Pao, Vincent A. Miller, Vikram K. Chand, Yali Fu, Bushi Wang, Gregory J. Riely, D. Ross Camidge, Scott Gettinger, Leora Horn, Harry J.M. Groen, Egbert F. Smit, Yelena Y. Janjigian
Adverse events of any grade.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc2f2bb3f801ec0d538a11c2271ee8d4
https://doi.org/10.1158/2159-8290.22532278
https://doi.org/10.1158/2159-8290.22532278
Autor:
Julian Downward, Katerina Politi, Egbert F. Smit, René Bernards, Harold Varmus, Marc Ladanyi, Yixuan Gong, Almudena García-Castaño, Javier Gómez-Román, Daniëlle A.M. Heideman, Guus J. Heynen, Anna Wurtz, Zenta Walther, Scott Gettinger, Mary Ann Melnick, Rebecca E. Saunders, Ming Jiang, Patricia H. Warne, Catherine Cowell, Elza C. de Bruin
PDF file 108K, Table S4. Clinical characteristics of human lung adenocarcinoma samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17fc1bd0ab84567b3626be4fede6e78f
https://doi.org/10.1158/2159-8290.22529726
https://doi.org/10.1158/2159-8290.22529726